News
Collaboration to support new mums in South Africa launched
The initiative has the potential to reach as many as one million women across South Africa
A new collaboration aimed at supporting new mothers across South Africa has been launched.
As part of the partnership, the National Department of Health in South Africa, nonprofit organisation Reach Digital Health and digital health company Ada will integrate an intelligent symptom-assessment technology with South Africa’s MomConnect mobile maternal health platform in an effort to improve women’s access to medical advice and care guidance.
The initiative, funded by The Rockefeller Foundation, has the potential to reach as many as one million active women on MomConnect.
According to a report by the World Health Organization (WHO), a woman dies every two minutes due to pregnancy or childbirth. Around 70 per cent of all maternal deaths are in sub-Saharan Africa.
Women aged 15 and above in low-income countries have a one in 49 chance of dying from maternal causes while in high-income countries the chance of dying is one in 5,300.
Berlin-based Ada aims to address this issue by integrating its AI-powered symptom assessment technology into the South African National Department Of Health’s digital health initiative MomConnect and into maternal and child health services.
The technology is hoped to help women better understand their symptoms through a series of questions based on clinically validated AI and protocols, enabling them to access appropriate services and support.
A preliminary evaluation conducted by Ada showed that over 50 per cent of the women surveyed who received treatment were not planning to seek care before using the company’s technology.
More than half of mothers who ended up in emergency care were not intending to do so prior to an assessment, the company also found.
“Technology has the power to improve maternal health outcomes by improving access to relevant advice for new and expectant mothers while bolstering existing health systems by alleviating pressure on health services,” said Hila Azadzoy, managing director of Ada’s Global Health Initiative.
“Ada’s AI-powered symptom assessment platform has been adapted to local linguistic, cultural, and healthcare requirements to make it accessible to as many individuals as possible.”
Debbie Rogers, chief executive officer of Reach Digital Health, said: “The need to provide accessible, regular and accurate healthcare guidance at a time when mothers and children need it most has never been more urgent.
“Integrating Ada’s intelligent health technology with the MomConnect mobile platform has the potential to build on the South African National Department Of Health’s aims of providing more equitable care and improving the health outcomes in the region.”
Naveen Rao, senior vice president, health at The Rockefeller Foundation, added: “Safeguarding the health and wellbeing of women and children should always be prioritised, and even more so during a health crisis.
“Technology offers us an opportunity to reach the most vulnerable with essential health services, and The Rockefeller Foundation is proud to support Ada and Reach Digital Health’s innovative approach to making this a reality in South Africa.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






